Overview

Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
To evaluate efficacy and safety of valsartan 160mg in Chinese hypertensive patients.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Valsartan